Results 221 to 230 of about 1,274,518 (371)

Positive Feedback Regulation between KLF5 and XPO1 Promotes Cell Cycle Progression of Basal like Breast Cancer

open access: yesAdvanced Science, EarlyView.
KLF5 is highly expressed in BLBC patients and promotes Cyclin D1 and XPO1 transcription, ultimately leading to the inactivation of RB1. Both XPO1 inhibitor (KPT‐330) and CDK4/6 inhibitor (Palbociclib) can enhance RB1 activity and exert antitumor effects. It has been proved that the combination of KPT‐330 and Palbociclib can inhibit the proliferation of
Yu Tang   +12 more
wiley   +1 more source

RNAlater facilitates remote sampling of aquaculture Atlantic salmon liver for proteomic analysis

open access: yesAquaculture, Fish and Fisheries, Volume 2, Issue 6, Page 578-586, December 2022., 2022
Graphical Abstract Proteomes of similar sizes were obtained in samples preserved by snap‐freezing or RNAlater. Proteins involved in transcriptional and translational machinery were affected in RNAlater stored samples. Abundance of published markers for heat and oxidative stress was not affected by snap‐freezing or RNAlater.
Anca G. Rusu   +6 more
wiley   +1 more source

Strategies to Detect Chromosomal Anomalies Not Identified by NIPT. [PDF]

open access: yesPrenat Diagn
Scott F   +4 more
europepmc   +1 more source

Genome‐Wide Association Studies Reveal the Genetic Architecture of Ionomic Variation in Grains of Tartary Buckwheat

open access: yesAdvanced Science, EarlyView.
In this study, variation and genetic basis of ionome among Tartary buckwheat population are investigated, illuminating their significance in the domestication and diversification of Tartary buckwheat. And three genes (FtACA13 for Na content, FtYPQ1 for Zn content, FtNHX2 for As content) are identified with the dominant haplotypes and functional ...
Zhirong Wang   +18 more
wiley   +1 more source

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant

open access: yesAmerican Journal of Hematology, Volume 98, Issue 1, Page 159-165, January 2023., 2023
Donor stem cell product undergoes CD34 stem cell selection. CD34 positive stem cells are used for transplantation. Pathogen‐ and leukemia‐specific T‐cells are manufactured from CD34 negative fraction and infused prophylactically 21 days after transplant.
David J. Gottlieb   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy